Combining behavioral and pharmacological treatments for obesity (Q34675924)

3 August 2017

1 reference

title

Combining behavioral and pharmacological treatments for obesity (English)

1 reference

3 August 2017

0 references

1 reference

Suzanne Phelan

1

0 references

Thomas A Wadden

series ordinal

2

object named as

Thomas A Wadden

1 reference

3 August 2017

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

10

1 reference

3 August 2017

6

1 reference

3 August 2017

560-574

1 reference

What is the role of cognitive-behavior therapy in patient management?

3 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Behavioral treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Descriptive epidemiology of body weight and weight change in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Effects of exercise-focused versus weight-focused maintenance programs on the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Changes in self-efficacy following obesity treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Physical activity and long-term maintenance of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Serotonin, eating behavior, and fat intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Sibutramine in weight control: a dose-ranging, efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Physical fitness and all-cause mortality. A prospective study of healthy men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Epidemiologic data linking diet to hyperlipidemia and arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Reinforcing value of food in obese and non-obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats: a long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

How "blind" are double-blind studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Using Internet technology to deliver a behavioral weight loss program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Lifestyle intervention in overweight individuals with a family history of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

The Eating Inventory in obese women: clinical correlates and relationship to weight loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

A descriptive study of individuals successful at long-term maintenance of substantial weight loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Sibutramine reduces food intake in non-dieting women with obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Modalities of the food intake-reducing effect of sibutramine in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

31 March 2020

Orlistat and weight loss

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Behavior therapy and pharmacotherapy for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Sequencing of behavior therapy and pharmacotherapy for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Couples Training, Pharmacotherapy, and Behavior Therapy in the Treatment of Obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

A double-blind randomized placebo-controlled trial of sibutramine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Fluoxetine's effect on weight loss in obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Treatment with orlistat reduces cardiovascular risk in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Metabolic and weight-loss effects of a long-term dietary intervention in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

Therapist and group contact as variables in the behavioral treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

Use of personal trainers and financial incentives to increase exercise in a behavioral weight-loss program

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

Effects of four maintenance programs on the long-term management of obesity

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

Enhancing the efficacy of behavior therapy for obesity: effects of aerobic exercise and a multicomponent maintenance program

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

Mechanisms of action in cognitive-behavioral and pharmacological interventions for obesity and bulimia nervosa

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.77

7 January 2021

Identifiers

DOI

10.1038/OBY.2002.77

1 reference

3 August 2017

1 reference

PubMed ID

12055334